Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi 110029, India.
J Clin Endocrinol Metab. 2012 Dec;97(12):4709-16. doi: 10.1210/jc.2012-2340. Epub 2012 Aug 17.
Randomized control trials (RCT) of the effect of vitamin D/calcium supplementation on skeletal muscle strength have not shown promising effect in the elderly.
Our objective was to assess the effect of vitamin D and/or calcium on muscle strength in young adults with vitamin D deficiency.
We conducted a RCT using a factorial design at a tertiary-care center from September 2010 to April 2011.
A total of 173 healthy females with mean age, body mass index, and 25-hydroxyvitamin D [25(OH)D] of 21.7 ± 4.4 yr, 20.8 ± 2.96 kg/m(2), and 9.3 ± 3.37 ng/ml, respectively, were block randomized to 1) double placebo, 2) calcium/placebo, 3) cholecalciferol/placebo, and 4) cholecalciferol/calcium for 6 months. Cholecalciferol was given at 60,000 IU/wk for 8 wk followed by 60,000 IU/fortnight. Elemental calcium was given in doses of 500 mg twice per day for 6 months.
Assessment included hand grip (primary outcome) and pinch grip strength, distance walked in 6 min, dyspnea score, quality of life by Short Form (36) Health Survey (SP-36), serum 25(OH)D, 1,25-dihydroxyvitamin D, and intact PTH.
The serum 25(OH)D increased significantly to 29.9 ± 8.35 and 27.0 ± 9.54 ng/ml in two groups on cholecalciferol. The mean hand grip strength (19.4 ± 3.92, 21.1 ± 3.31, 20.6 ± 3.92, and 20.1 ± 4.00 kg) and its increase from baseline (0.3 ± 2.25, 0.3 ± 2.64, -0.3 ± 2.41, and 0.6 ± 2.30 kg) were comparable in four groups at 6 months. Quality of life, urinary calcium/creatinine ratio, and adverse effects were also comparable in groups.
Oral cholecalciferol/calcium supplementation in the dose/schedule used is effective and safe in increasing and maintaining serum 25(OH)D. However, this does not lead to improved skeletal muscle strength in young females.
关于维生素 D/钙补充剂对骨骼肌肉力量影响的随机对照试验(RCT)并未显示出对老年人的显著效果。
我们的目的是评估维生素 D 和/或钙对维生素 D 缺乏的年轻成年人肌肉力量的影响。
我们在 2010 年 9 月至 2011 年 4 月期间在一家三级保健中心进行了一项使用析因设计的 RCT。
共有 173 名健康女性,平均年龄、体重指数和 25-羟维生素 D [25(OH)D]分别为 21.7 ± 4.4 岁、20.8 ± 2.96 kg/m(2)和 9.3 ± 3.37 ng/ml,按块随机分为 1)双安慰剂、2)钙/安慰剂、3)胆钙化醇/安慰剂和 4)胆钙化醇/钙,为期 6 个月。胆钙化醇每周给予 60,000 IU,持续 8 周,然后每两周给予 60,000 IU。元素钙每天分两次给予 500 mg,持续 6 个月。
评估包括手握力(主要结局)和捏力强度、6 分钟步行距离、呼吸困难评分、健康调查简表(36)(SP-36)的生活质量、血清 25(OH)D、1,25-二羟维生素 D 和完整甲状旁腺激素。
在胆钙化醇组中,血清 25(OH)D 显著增加至 29.9 ± 8.35 和 27.0 ± 9.54 ng/ml。两组的平均手握力(19.4 ± 3.92、21.1 ± 3.31、20.6 ± 3.92 和 20.1 ± 4.00 kg)及其与基线相比的增加量(0.3 ± 2.25、0.3 ± 2.64、-0.3 ± 2.41 和 0.6 ± 2.30 kg)在 6 个月时在四组中相似。各组的生活质量、尿钙/肌酐比值和不良反应也相似。
在使用的剂量/方案中口服胆钙化醇/钙补充剂是有效和安全的,可以增加和维持血清 25(OH)D。然而,这并没有导致年轻女性的骨骼肌肉力量得到改善。